The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|September 16, 2010
Regulatory Roundup: ISPE to Hold Risk-MaPP 2010 Conference
Author(s)Pharmaceutical Technology Editors
ISPE to Hold Risk-MaPP 2010 Conference
Advertisement
The International Society for Pharmaceutical Engineering (ISPE) will host the ISPE Risk-MaPP 2010 Conference, Dedicated Facilities, Cross Contamination and the Risk-MaPP Approach in Washington, DC, on October 4–5 2010. The group will hold the North American launch of the new ISPE Baseline Guide: Risk-Based Manufacturing of Pharmaceutical Products (Risk-MaPP) at the conference, and attendees will receive a complimentary downloadable copy of the guide. To register for the conference, click
Advertisement
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Advertisement
Advertisement